(Q33987625)

30 July 2017

Gastrointestinal manifestations of Fabry disease: clinical response to enzyme replacement therapy (English)

1 reference

enzyme replacement therapy

30 July 2017

0 references

1 reference

3

Robert J Desnick

1 reference

30 July 2017

Maryam Banikazemi

1

1 reference

PubMed ID

15939645

30 July 2017

Thomas Ullman

series ordinal

2

1 reference

30 July 2017

1 August 2005

1 reference

Molecular Genetics and Metabolism

30 July 2017

1 reference

30 July 2017

85

1 reference

30 July 2017

4

1 reference

30 July 2017

255-259

1 reference

Anderson-Fabry disease: clinical manifestations and impact of disease in a cohort of 98 hemizygous males

30 July 2017

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2005.04.009

Relief of gastrointestinal symptoms under enzyme replacement therapy [corrected] in patients with Fabry disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2005.04.009

Assessment of health-related quality-of-life in males with Anderson Fabry Disease before therapeutic intervention

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2005.04.009

Quality of life of patients with Fabry disease.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2005.04.009

Anderson-Fabry disease: clinical manifestations and impact of disease in a cohort of 60 obligate carrier females

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2005.04.009

Novel frameshift mutation in a heterozygous woman with Fabry disease and end-stage renal failure.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2005.04.009

An atypical variant of Fabry's disease in men with left ventricular hypertrophy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2005.04.009

Fabry disease: detection of undiagnosed hemodialysis patients and identification of a "renal variant" phenotype

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2005.04.009

Fabry disease defined: baseline clinical manifestations of 366 patients in the Fabry Outcome Survey

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2005.04.009

Clinical features of Fabry's disease in Australian patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2005.04.009

Clinical manifestation in female Fabry disease patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2005.04.009

Intestinal manifestations of Fabry's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2005.04.009

Fabry disease: impaired autonomic function.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2005.04.009

Gastrointestinal symptoms and delayed gastric emptying in Fabry's disease: response to metoclopramide

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2005.04.009

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2005.04.009

Achalasia in an adolescent with Fabry disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2005.04.009

A phase 1/2 clinical trial of enzyme replacement in fabry disease: pharmacokinetic, substrate clearance, and safety studies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2005.04.009

Safety and efficacy of recombinant human alpha-galactosidase A replacement therapy in Fabry's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2005.04.009

Globotriaosylceramide accumulation in the Fabry kidney is cleared from multiple cell types after enzyme replacement therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2005.04.009

Monitoring the 3-year efficacy of enzyme replacement therapy in fabry disease by repeated skin biopsies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2005.04.009

Long-term safety and efficacy of enzyme replacement therapy for Fabry disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2005.04.009

The early clinical phenotype of Fabry disease: a study on 35 European children and adolescents.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2005.04.009

Effect of enzyme-replacement therapy on gastrointestinal symptoms in Fabry disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2005.04.009

10.1016/J.YMGME.2005.04.009

7 January 2021

Identifiers

DOI

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/2ftcmpqbsrbojex3zdp367njvi

mapped directly with Wikidata item

30 July 2022

based on heuristic

Fatcat ID

release_2ftcmpqbsrbojex3zdp367njvi

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/2ftcmpqbsrbojex3zdp367njvi

mapped directly with Wikidata item

30 July 2022

based on heuristic

1 reference

https://api.fatcat.wiki/v0/release/2ftcmpqbsrbojex3zdp367njvi